1. Home
  2. Research
  3. Research Groups
  4. Multiple Sclerosis

Multiple Sclerosis

Search for publications

Only original articles, editorials, guidelines.

  • Sainz de la Maza S, Maurino J, Castillo-Triviño T, Borges M, Sebastián Torres B, Sotoca J, Alonso Torres AM, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, Dotor García-Soto J, Rodríguez-Regal A, Navarro-Cantó L, Agüera-Morales E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, Gómez-Ballesteros R.

    Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.

    PATIENT PREFERENCE AND ADHERENCE . 17: 1431-1439.

    [doi:10.2147/PPA.S411069]

  • Muñoz-San Martín M, Gómez I, Quiroga-Varela A, Gonzalez-Del Río M, Robles Cedeño R, Álvarez G, Buxó M, Miguela A, Villar LM, Castillo-Villalba J, Casanova B, Quintana E, Ramió-Torrentà L.

    miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

    Neurology(R) neuroimmunology & neuroinflammation . 10(1): .

    [doi:10.1212/NXI.0000000000200069]

  • Fissolo N, Pappolla A, Rio J, Villar LM, Perez-Hoyos S, Sanchez A, Gutierrez L, Montalban X, Comabella M.

    Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.

    Neurology(R) neuroimmunology & neuroinflammation . 10(1): . Number of citations: 1

    [doi:10.1212/NXI.0000000000200050]

  • Klett-Mingo JI, Pinto-Díez C, Cambronero-Plaza J, Carrión-Marchante R, Barragán-Usero M, Pérez-Morgado MI, Rodríguez-Martín E, Toledo-Lobo MV, González VM, Martín ME.

    Potential Therapeutic Use of Aptamers against HAT1 in Lung Cancer.

    Cancers . 15(1): .

    [doi:10.3390/cancers15010227]

  • Fernández-Fournier M, Lacruz L, Nozal P, Chico JL, Tallón Barranco A, Otero-Ortega L, Corral I, Carrasco A.

    The study of neural antibodies in neurology: A practical summary.

    Frontiers in immunology . 13: 1043723-1043723.

    [doi:10.3389/fimmu.2022.1043723]

  • Cobeta P, Pariente R, Osorio A, Marchan M, Blázquez L, Pestaña D, Galindo J, Botella-Carretero JI.

    The Beneficial Changes on Inflammatory and Endothelial Biomarkers Induced by Metabolic Surgery Decreases the Carotid Intima-Media Thickness in Men.

    Biomolecules . 12(12): .

    [doi:10.3390/biom12121827]

  • Coll-Martinez C, Quintana E, Buxó M, Salavedra-Pont J, Gasull-Vicens L, Quiroga-Varela A, Costa-Frossard L, Villar LM, Fernández-Díaz E, Gracia J, Aladro Y, Méndez-Burgos A, Cerezo M, Ramió-Torrentà L, Gich J.

    Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 68: 104397-104397.

    [doi:10.1016/j.msard.2022.104397]

  • Chico-García JL, Rodríguez-Jorge F, Sainz-Amo R, Monreal E, Walo-Delgado P, Roldán E, Rodríguez-Martín E, Masjuan J, Costa-Frossard L, Sainz de la Maza S, Villar LM.

    B-lymphocyte-guided retreatment contributes to establish good effectiveness and safety profile in MS patients treated with rituximab.

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 68: 104218-104218.

    [doi:10.1016/j.msard.2022.104218]

  • Saposnik G, Andhavarapu S, Sainz de la Maza S, Castillo-Triviño T, Borges M, Barón BP, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, García-Soto JD, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, García-Arcelay E, Terzaghi M, Gómez-Ballesteros R, Maurino J.

    Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis

    MULTIPLE SCLEROSIS AND RELATED DISORDERS . 68: 104138-104138.

    [doi:10.1016/j.msard.2022.104138]

  • Camacho-Toledano C, Machín-Díaz I, Calahorra L, Cabañas-Cotillas M, Otaegui D, Castillo-Triviño T, Villar LM, Costa-Frossard L, Comabella M, Midaglia L, García-Domínguez JM, García-Arocha J, Ortega MC, Clemente D.

    Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

    JOURNAL OF NEUROINFLAMMATION . 19(1): 277-277. Number of citations: 3

    [doi:10.1186/s12974-022-02635-3]

  • Cogram P, Fernández-Beltrán LC, Casarejos MJ, Sánchez-Yepes S, Rodríguez-Martín E, García-Rubia A, Sánchez-Barrena MJ, Gil C, Martínez A, Mansilla A.

    The inhibition of NCS-1 binding to Ric8a rescues fragile X syndrome mice model phenotypes.

    FRONTIERS IN NEUROSCIENCE . 16: 1007531-1007531.

    [doi:10.3389/fnins.2022.1007531]

  • Domínguez-Mozo MI, García-Frontini Nieto MC, Gómez-Calcerrada MI, Pérez-Pérez S, García-Martínez MÁ, Villar LM, Villarrubia N, Costa-Frossard L, Arroyo R, Alvarez-Lafuente R.

    Mitochondrial Impairments in Peripheral Blood Mononuclear Cells of Multiple Sclerosis Patients.

    BIOLOGY-BASEL . 11(11): .

    [doi:10.3390/biology11111633]

  • Baena-Álvarez B, Rodríguez-Jorge F, Beltrán-Corbellini Á, Cortés-Salgado A, De la Puente C, Corral Í.

    Progressive multifocal leukoencephalopathy, advanced ductal breast carcinoma, systemic sclerosis, and checkpoint inhibitors: a therapeutic dilemma.

    JOURNAL OF NEUROVIROLOGY . 29(1): 116-119.

    [doi:10.1007/s13365-022-01103-1]

  • Mexhitaj I, Lim N, Fernandez-Velasco JI, Zrzavy T, Harris KM, Muraro PA, Villar LM, Bar-Or A, Cooney LA.

    Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials.

    JOURNAL OF IMMUNOLOGICAL METHODS . 510: 113344-113344.

    [doi:10.1016/j.jim.2022.113344]

  • Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Plata M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X.

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.

    Neurologia . 37(8): 615-630. Number of citations: 1

    [doi:10.1016/j.nrleng.2019.11.001]

  • Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Platas M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X.

    Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    NEUROLOGIA . 37(8): 615-630. Number of citations: 2

    [doi:10.1016/j.nrl.2019.11.003]

  • Meca-Lallana JE, Gómez-Ballesteros R, Pérez-Miralles F, Forero L, Sepúlveda M, Calles C, Martínez-Ginés ML, González-Suárez I, Boyero S, Romero-Pinel L, Sempere ÁP, Meca-Lallana V, Querol L, Costa-Frossard L, Prefasi D, Maurino J.

    Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study

    Neurology and Therapy . 11(3): 1101-1116. Number of citations: 2

    [doi:10.1007/s40120-022-00356-6]

  • Cobeta P, Pariente R, Osorio A, Marchan M, Cuadrado-Ayuso M, Pestaña D, Galindo J, Botella-Carretero JI.

    The Role of Adiponectin in the Resolution of Male-Obesity-Associated Secondary Hypogonadism after Metabolic Surgery and Its Impact on Cardiovascular Risk.

    Biomedicines . 10(8): . Number of citations: 1

    [doi:10.3390/biomedicines10082000]